<!DOCTYPE html>

<html lang="en">
<head>
<meta charset="utf-8"/>
<title>article241</title>
<style>
        body {
            font-family: Arial, sans-serif;
            margin: 0;
            padding: 0;
            background-color: #f3f3f3;
        }
        .container {
            max-width: 800px;
            margin: auto;
            background: #fff;
            padding: 20px;
            box-shadow: 0 0 10px rgba(0, 0, 0, 0.1);
        }
        h1, h2 {
            color: #333;
        }
        p {
            line-height: 1.6;
        }
        a {
            text-decoration: none;
            color: #5a5a5a;
        }
        a:hover {
            color: #000;
        }
    </style>
</head>
<body>
<div class="container"><p><a href="../index_gpt.html">Back to Index</a></p><li><a href="https://www.wikijournalclub.org/wiki/WARFASA" style="display:block; margin-bottom:10px;">WARFASA Original</a></li>
<h2><strong>WARFASA</strong></h2>
<div class="container">
<h2><strong></strong></h2>
<div class="container">
<div class="container">
<h2><strong></strong></h2>
<h2><strong></strong></h2>

    "Aspirin for the Secondary Prevention of Venous Thromboembolism". The New England Journal of Medicine. 2012. 366:1959-1967. PubMed•Full text•PDF<br/>
<br/>
<h2><strong>Contents</strong></h2><br/>
1 Clinical Question<br/>
2 Bottom Line<br/>
3 Major Points<br/>
4 Guidelines<br/>
5 Design<br/>
6 Population<br/>
6.1 Inclusion Criteria<br/>
6.2 Exclusion Criteria<br/>
6.3 Baseline Characteristics<br/>
7 Interventions<br/>
8 Outcomes<br/>
8.1 Primary Outcome<br/>
8.2 Secondary Outcomes<br/>
9 Funding<br/>
10 Further Reading<br/>
<br/>
<h2><strong>Clinical Question</strong></h2><br/>
In patients with unprovoked venous thromboembolism who have completed 6 to 18 months of oral anticoagulant treatment, does aspirin reduce the risk of recurrence without increasing the risk of major bleeding compared with placebo?<br/>
<br/>
<h2><strong>Bottom Line</strong></h2><br/>
Aspirin reduces the risk of recurrent venous thromboembolism by about 40% after discontinuation of anticoagulant treatment, without a significant increase in major bleeding events.<br/>
<br/>
<h2><strong>Major Points</strong></h2><br/><br/>
<br/>
<h2><strong>Guidelines</strong></h2><br/>
Current guidelines may not yet reflect the findings of this trial.<br/>
<br/>
<h2><strong>Design</strong></h2><br/>
- Multicenter, investigator-initiated, double-blind, randomized, placebo-controlled trial<br/>
- N=402 patients with unprovoked venous thromboembolism<br/>
- Aspirin 100 mg daily (n=205) or placebo (n=197)<br/>
- Median follow-up: 24.6 months<br/>
- Analysis: Modified intention-to-treat<br/>
- Primary efficacy outcome: Recurrence of venous thromboembolism<br/>
- Primary safety outcome: Major bleeding<br/>
<br/>
<h2><strong>Population</strong></h2><br/>
Inclusion Criteria<br/>
- Age over 18 years<br/>
- Completed 6 to 18 months of vitamin K antagonist treatment for first-ever, unprovoked proximal deep-vein thrombosis or pulmonary embolism<br/>
<br/>
Exclusion Criteria<br/>
- Venous thromboembolism provoked by a known risk factor<br/>
- Patients with significant bleeding during initial anticoagulant treatment or with other conditions contraindicating aspirin use (see Supplementary Appendix for detailed criteria)<br/>
<br/>
Baseline Characteristics<br/>
- Demographics, clinical characteristics, and comorbidities balanced between the two groups<br/>
<br/>
<h2><strong>Interventions</strong></h2><br/>
- Aspirin, 100 mg once daily, or placebo for 2 years, with the option to extend treatment<br/>
<br/>
<h2><strong>Outcomes</strong></h2><br/>
Primary Outcome<br/>
- Recurrent venous thromboembolism occurred in 28 of the 205 patients in the aspirin group and in 43 of the 197 patients in the placebo group (6.6% vs. 11.2% per year; hazard ratio, 0.58; 95% CI, 0.36 to 0.93; P=0.02)<br/>
<br/>
Secondary Outcomes<br/>
- Two major bleeding events, one in each treatment group<br/>
- Additional secondary efficacy outcomes included nonfatal myocardial infarction, unstable angina, stroke, transient ischemic attack, acute ischemia of the lower limbs, and death from any cause<br/>
<br/>
<h2><strong>Funding</strong></h2><br/>
- University of Perugia, grant-in-aid from Bayer HealthCare, and an Aventis Fellowship for Clinical Research from the International Society of Thrombosis and Haemostasis.<br/>
<br/>
<h2><strong>Further Reading</strong></h2><br/>
- Original article in The New England Journal of Medicine<br/>
- Supplementary Appendix available at NEJM.org
    <p></p>
</div>
</div>
</div>
</div>
</body>
</html>
